Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437133 | 0.98 | TSHR (0.46) | TSHRALDH1A1CYP3A4PDE7ACYP1A2 | |
| SCHEMBL3612247 | 0.86 | TDP1 (0.54) | TSHRALDH1A1CYP3A4CYP1A2TDP1 | |
| SCHEMBL629679 | 0.80 | TSHR (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL259813 | 0.80 | TSHR (0.60) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL1330407 | 0.80 | TSHR (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL10610184 | 0.80 | ALDH1A1 (0.47) | TSHRALDH1A1CYP3A4PDE7ATDP1 | |
| SCHEMBL18829958 | 0.80 | CYP1A2 (0.55) | TSHRALDH1A1CYP3A4CYP1A2RECQL | |
| SCHEMBL8903476 | 0.80 | ALDH1A1 (0.55) | TSHRALDH1A1CYP3A4PDE7ATDP1 | |
| SCHEMBL3864393 | 0.80 | TSHR (0.54) | TSHRALDH1A1CYP3A4CYP1A2TDP1 | |
| SCHEMBL938651 | 0.78 | GPR35 (0.61) | TSHRALDH1A1CYP3A4CYP1A2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102372675-B | 6-chlorine-4-iodine indazole, preparation method and application thereof | WANG NA | 2013-12-18 | — | — | CN | disclosed |
| CN-102372675-A | 6-chlorine-4-iodine indazole, preparation method and application thereof | SHENZHEN INOVA MEDICAL TECHNOLOGY DEV CO LTD | 2012-03-14 | — | — | CN | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| CN-101553492-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-10-07 | — | — | CN | disclosed |
| EP-2057168-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | disclosed |
| CN-1262547-C | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
| CN-1176910-C | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | - | 2004-11-24 | — | — | CN | disclosed |
| CN-1515562-A | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | - | 2004-07-28 | — | — | CN | disclosed |
| CN-1515559-A | Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative | - | 2004-07-28 | — | — | CN | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| CN-1203228-A | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | HOFFMANN LA ROCHE (CH) | 1998-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TSHR 2513/4885ALDH1A1 985/4885CYP3A4 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.